Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Authors' conclusion
Once-weekly basal insulin efsitora alfa is well tolerated with glycemic efficacy similar to once-daily degludec.
Study context
- Population
- Subjects with T1D and T2D
- Participants
- 2,465 subjects6 studies
- Comparison
- Once-weekly efsitora alfa vs once-daily basal insulin
- Outcome
- Change from baseline in HbA1c
Pooled result
As reported in the abstract
follow-up 26-54 weeks
Efsitora alfa vs Once-daily basal insulinMD, % (CI)P value
T2D; comparable HbA1c reduction
0.02(−0.11 to 0.16)
P = 0.74T1D; comparable HbA1c reduction
0.11(−0.01 to 0.22)
P = 0.08Further pooled results
FPG and achieving HbA1c < 7% (T2D)
- Efsitora and degludec similarly effective in reducing FPG and achieving HbA1c < 7% in T2D
TIR, TAR, TBR (T2D and T1D)
- Comparable TIR, TAR and TBR in T2D and T1D
Safety
| Outcome | RR (CI) | P value | |
|---|---|---|---|
| Nocturnal hypoglycemia (T2D)Lower with efsitora | 0.85 (0.74–0.98) | P = 0.03 | |
| 0.512Relative risk (log scale) |
Other safety outcomes (T2D)
- Comparable total AEs, severe AEs, injection-site reactions, hypersensitivity events, and overall and severe hypoglycemia in T2D
Safety (T1D)
- Total AEs, severe AEs and injection-site reactions higher with efsitora in T1D; comparable hypersensitivity events and overall, severe and nocturnal hypoglycemia
Original publication
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocr Pract. Published 20 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →